# FDA Grants Accelerated Approval to AstraZeneca’s Camizestrant for ctDNA-Guided Breast Cancer Treatment

The U.S. Food and Drug Administration has granted accelerated approval to AstraZeneca’s camizestrant, brand name Etcamah, for a molecular-guided breast cancer indication. The decision marks a rare divergence from the agency’s own expert advisory panel, which had previously reviewed the drug. The approval opens a new treatment paradigm based on circulating tumor DNA (ctDNA) testing to guide therapy selection.

Camizestrant is a next-generation oral selective estrogen receptor degrader (SERD). The accelerated approval pathway allows the drug to reach patients based on surrogate endpoints, with confirmatory trials required for full approval. The regulatory review had been contentious, making the final decision a landmark win for AstraZeneca and for the broader concept of molecular-guided cancer care.

**Context for biotech and medicine**

This approval signals a shift toward using ctDNA as a biomarker to match patients with targeted therapies in breast cancer, moving beyond traditional tissue-based testing. ctDNA analysis offers a non-invasive way to detect tumor mutations and monitor disease progression. For the life sciences, it underscores the growing integration of liquid biopsy technology into regulatory decision-making and clinical practice. The accelerated approval mechanism also highlights the FDA’s willingness to support novel endpoints in oncology, even when advisory committees disagree.

Source: [original report](https://www.fiercebiotech.com/pharma/fda-approves-astrazeneca-etcamah-opening-ctdna-guided-treatment-shift-breast-cancer)